BTIG reaffirmed its "Buy" rating for NASDAQ:ABVX, increasing the price target from $112 to $120.Abivax's experimental drug, obefazimod, shows promising results in treating ulcerative colitis, leading to remission in patients unresponsive to previous therapies.The drug's success boosts its strategic appeal, indicating strong interest from larger pharmaceutical companies amid rising mergers and acquisitions.Abivax (NASDAQ:ABVX) is a prominent biotech company known for its innovative treatments in the field of ...